You're back Benny! It's a Christmas miracle.
Yes, it's all well and good to dose mice and test tubes, but as you say nothing in this class has been effective in human clinical trials.
The other big concern with NYR is that they don't have patent protection for this drug. That will keep the share price heading downwards until it's secured.
And unfortunately having to run a Phase 1a and then a Phase 1b for 2+ years means we probably can't expect any share price catalyst or news flow until 2027.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.025(10.2%) |
Mkt cap ! $46.40M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 22.0¢ | $256.0K | 1.085M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 67420 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 25083 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |